scholarly journals Effects of the tai chi qigong programme on functional capacity, and lung function in chronic obstructive pulmonary disease patients: A ramdomised controlled trial

2020 ◽  
Vol 10 (4) ◽  
pp. 354-359 ◽  
Author(s):  
Tassawan Kantatong ◽  
Ratana Panpanich ◽  
Athavudh Deesomchok ◽  
Somporn Sungkarat ◽  
Penprapa Siviroj
2016 ◽  
Vol 24 (2) ◽  
pp. 216-224 ◽  
Author(s):  
Eva Broendum ◽  
Charlotte Suppli Ulrik ◽  
Thorbjorn Gregersen ◽  
Ejvind Frausing Hansen ◽  
Allan Green ◽  
...  

The aim of this analysis is to investigate reasons why patients with chronic obstructive pulmonary disease decline to participate in a controlled trial of telemedicine. Patients with previous chronic obstructive pulmonary disease exacerbations were invited to participate in a 6-month randomized telemedicine trial. For eligible patients, reasons for refusal were registered. Of 560 eligible patients, 279 (50%) declined to participate in the trial, 257 (92%) reported a reason: 53 (20.6%) technical concerns, 164 (63.8%) personal reasons, 17 (6.6%) preferred outpatient clinic visits, and 23 (8.9%) did not want to participate in clinical research. Compared to consenting patients, subjects declining participation were significantly older, more often female, had higher lung function (%predicted), lower body mass index, higher admission-rate for chronic obstructive pulmonary disease in the previous year, and were more often diagnosed with osteoporosis. Many eligible patients decline participating in a controlled tele-healthcare trial and, furthermore, a tailored approach for recruiting females and elderly patients appears appropriate.


2007 ◽  
Vol 14 (8) ◽  
pp. 465-472 ◽  
Author(s):  
Charles KN Chan ◽  
François Maltais ◽  
Chris Sigouin ◽  
Jennifer M Haddon ◽  
Gordon T Ford ◽  
...  

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) who smoke have a greater annual rate of decline in forced expiratory volume in 1 s (FEV1) than those patients who have stopped smoking.OBJECTIVES: To assess the effect of tiotropium on pre-dose (trough) FEV1in patients with COPD followed in Canada.METHODS: A total of 913 patients were randomly assigned to receive either tiotropium 18 μg once daily (n=608) or placebo (usual care minus inhaled anticholinergics) (n=305) for 48 weeks in the present randomized, double-blind, parallel-group study. The effect of tiotropium on measurements of lung function (FEV1, FEV6and forced vital capacity), symptoms, health-related quality of life (St George’s Respiratory Questionnaire) and exacerbations were examined.RESULTS: Tiotropium improved trough FEV1in both current and ex-smokers compared with placebo. Baseline FEV1in smokers and ex-smokers was 1.03 L and 0.93 L, respectively (P<0.001). At week 48, the mean difference between the tiotropium and placebo groups was 0.14±0.04 L (P<0.001) in the smoker group and 0.08±0.02 L (P<0.0001) in the ex-smoker group. Tiotropium also significantly improved trough forced vital capacity and FEV6compared with placebo throughout the treatment period (P<0.05, for all). Furthermore, tiotropium significantly improved the St George’s Respiratory Questionnaire total score compared with placebo at week 48 (40.9 versus 43.7 units, P<0.005).CONCLUSIONS: Compared with the placebo group, tiotropium provides sustained improvements in lung function in patients with COPD, with improvements for smokers and ex-smokers.


2009 ◽  
Vol 15 (2) ◽  
pp. 199-214
Author(s):  
Sérgio Leite Rodrigues ◽  
César Augusto Melo e Silva ◽  
Tereza Lima ◽  
Carlos Alberto de Assis Viegas ◽  
Marcelo Palmeira Rodrigues ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document